Note 5 - Collaboration and License Agreement (Details Textual) - USD ($) $ in Thousands		12 Months Ended		26 Months Ended
	Nov. 06, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022
Revenue from Contract with Customer, Excluding Assessed Tax, Total		$ 9,137	$ 7,442
Contract with Customer, Liability, Current		4,414	4,571	$ 4,414
Contract with Customer, Liability, Noncurrent		621	3,548	621
3D Medicines, Inc [Member]
Proceeds from Collaborators		15,000		27,000
Collaborative Agreement, Maximum Clinical Development, Regulatory and Commercial Milestone Payments	$ 207,000
Collaborative Agreement, Royalty, Period After First Commercial Sale of Product (Year)	10 years
Revenue, Remaining Performance Obligation, Amount		27,000		27,000
Contract with Customer, Liability, Total		5,000	8,100	5,000
Contract with Customer, Liability, Current		4,400		4,400
Contract with Customer, Liability, Noncurrent		600		600
Contract with Customer, Liability, Revenue Recognized		$ 5,300
Service Period (Year)		2 years
3D Medicines, Inc [Member] | Research and Development Services [Member]
Revenue, Remaining Performance Obligation, Amount		$ 14,500		14,500
Revenue from Contract with Customer, Excluding Assessed Tax, Total		6,300	3,200
3D Medicines, Inc [Member] | License [Member]
Revenue, Remaining Performance Obligation, Amount		12,500		$ 12,500
Revenue from Contract with Customer, Excluding Assessed Tax, Total		$ 2,800	$ 4,200